{"id":"abvd-q4-weeks","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"80-90","effect":"Alopecia"},{"rate":"30-50","effect":"Mucositis"},{"rate":"5-10","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"5-15","effect":"Pulmonary toxicity (bleomycin-related)"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL3903860","moleculeType":"Small molecule","molecularWeight":"448.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABVD combines doxorubicin (anthracycline), bleomycin (antibiotic), vinblastine (vinca alkaloid), and dacarbazine (alkylating agent). Each agent targets cancer cells through different mechanisms: doxorubicin intercalates DNA and inhibits topoisomerase II; bleomycin causes DNA strand breaks; vinblastine disrupts microtubule formation; and dacarbazine alkylates DNA. The combination provides synergistic cytotoxic effects across multiple pathways.","oneSentence":"ABVD is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:37.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABVD q4 weeks","genericName":"ABVD q4 weeks","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABVD is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}